Q3: 2025-11-06 Earnings Summary
EPS of $0.67 beats by $0.05
| Revenue of $3.76B (0.23% Y/Y) beats by $159.08M
Viatris Inc. (VTRS) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST
Company Participants
Theodora Mistras – Chief Financial Officer
Conference Call Participants
Ashwani Verma – UBS Investment Bank, Research Division
Presentation
Ashwani Verma
UBS Investment Bank, Research Division
Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma. Welcome to UBS Healthcare Conference. And with me really excited to have from Viatris, Theodora Mistras, who is the Chief Financial Officer. Theodora, thank you for joining us.
Theodora Mistras
Chief Financial Officer
Thank you so much for having me. It’s great to be here.
Question-and-Answer Session
Ashwani Verma
UBS Investment Bank, Research Division
Yes. So a lot of exciting things happening with your story. I want to learn more about what are the key updates. Maybe if you can just kind of give us a high-level thought on — you just reported third quarter earnings and where the story is and then we can get into…
Theodora Mistras
Chief Financial Officer
Thanks, Ash. We’re really pleased with the momentum in the business. We remain on track to deliver 2% to 3% operational revenue growth, excluding Indore. And as we look into 2026, we expect that positive momentum to continue.
We’re really focused on executing against our strategic priorities. The enterprise-wide review is ongoing. We’ve delivered 5 of 6 positive pipeline readouts in the first half of this year. And overall, we feel really good about the momentum.
And then finally, we’re also delivering on our capital allocation priorities. We’re on track to deliver over $1 billion of capital to shareholders, including $500 million of share repurchases this year.
Ashwani Verma
UBS Investment Bank, Research Division
Great. Awesome. So yes, I wanted to understand like some of the pushes and pulls on just the financials like going
